NO308413B1 - Antigen blanding, DNA-segment som koder for et antigen, rekombinant vektor og vertscelle som innbefatter DNA-segmentet samt anvendelser av et antigen - Google Patents

Antigen blanding, DNA-segment som koder for et antigen, rekombinant vektor og vertscelle som innbefatter DNA-segmentet samt anvendelser av et antigen

Info

Publication number
NO308413B1
NO308413B1 NO940502A NO940502A NO308413B1 NO 308413 B1 NO308413 B1 NO 308413B1 NO 940502 A NO940502 A NO 940502A NO 940502 A NO940502 A NO 940502A NO 308413 B1 NO308413 B1 NO 308413B1
Authority
NO
Norway
Prior art keywords
antigen
dna segment
omps
proteins
host cell
Prior art date
Application number
NO940502A
Other languages
English (en)
Other versions
NO940502D0 (no
NO940502L (no
Inventor
Eric J Hansen
Merja Helminen
Isobel Maciver
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO940502D0 publication Critical patent/NO940502D0/no
Publication of NO940502L publication Critical patent/NO940502L/no
Publication of NO308413B1 publication Critical patent/NO308413B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO940502A 1991-08-15 1994-02-14 Antigen blanding, DNA-segment som koder for et antigen, rekombinant vektor og vertscelle som innbefatter DNA-segmentet samt anvendelser av et antigen NO308413B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/745,591 US5552146A (en) 1991-08-15 1991-08-15 Methods and compositions relating to useful antigens of Moraxella catarrhalis
PCT/US1992/006869 WO1993003761A1 (en) 1991-08-15 1992-08-14 METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)

Publications (3)

Publication Number Publication Date
NO940502D0 NO940502D0 (no) 1994-02-14
NO940502L NO940502L (no) 1994-03-28
NO308413B1 true NO308413B1 (no) 2000-09-11

Family

ID=24997358

Family Applications (2)

Application Number Title Priority Date Filing Date
NO940502A NO308413B1 (no) 1991-08-15 1994-02-14 Antigen blanding, DNA-segment som koder for et antigen, rekombinant vektor og vertscelle som innbefatter DNA-segmentet samt anvendelser av et antigen
NO20002413A NO20002413L (no) 1991-08-15 2000-05-09 Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20002413A NO20002413L (no) 1991-08-15 2000-05-09 Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer

Country Status (14)

Country Link
US (3) US5552146A (no)
EP (1) EP0612250B1 (no)
JP (1) JP3499868B2 (no)
KR (1) KR100271888B1 (no)
AT (1) ATE140627T1 (no)
AU (1) AU666329B2 (no)
CA (1) CA2115565C (no)
DE (1) DE69212495T2 (no)
DK (1) DK0612250T3 (no)
ES (1) ES2092696T3 (no)
FI (1) FI106844B (no)
GR (1) GR3021423T3 (no)
NO (2) NO308413B1 (no)
WO (1) WO1993003761A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6290970B1 (en) * 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
KR100500000B1 (ko) * 1996-05-03 2005-12-12 안텍스 바이오로직스 인코퍼레이션 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
US6004562A (en) * 1996-08-16 1999-12-21 The Research Foundation Of The State University Of New York Outer membrane protein B1 of Moraxella catarrhalis
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
DE69740108D1 (de) 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
AU4260099A (en) * 1998-05-12 1999-11-29 Smithkline Beecham Biologicals (Sa) Compounds from moraxella catarrhalis
GB9810285D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) * 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
PL375408A1 (en) 2002-08-02 2005-11-28 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101730748B1 (ko) 2005-04-08 2017-04-26 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
DK3017827T3 (en) 2005-12-22 2019-02-18 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate VACCINE
KR20080096775A (ko) 2006-01-17 2008-11-03 아르네 포르스그렌 표면 노출된 헤모필루스 인플루엔자 단백질 （단백질 Ｅ ―ｐＥ）
WO2009000826A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
UA99659C2 (uk) 2008-05-30 2012-09-10 Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN102869378A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030556A (en) * 1989-03-30 1991-07-09 Danielle Beaulieu Species-specific DNNA probe for the detection of Branhamella catarrhalis

Also Published As

Publication number Publication date
NO20002413D0 (no) 2000-05-09
US5759813A (en) 1998-06-02
WO1993003761A1 (en) 1993-03-04
FI106844B (fi) 2001-04-30
ATE140627T1 (de) 1996-08-15
FI940681A (fi) 1994-04-07
GR3021423T3 (en) 1997-01-31
AU666329B2 (en) 1996-02-08
DE69212495D1 (de) 1996-08-29
NO20002413L (no) 2000-05-09
JP3499868B2 (ja) 2004-02-23
NO940502D0 (no) 1994-02-14
NO940502L (no) 1994-03-28
US5552146A (en) 1996-09-03
US5599693A (en) 1997-02-04
FI940681A0 (fi) 1994-02-14
ES2092696T3 (es) 1996-12-01
EP0612250B1 (en) 1996-07-24
EP0612250A1 (en) 1994-08-31
KR100271888B1 (ko) 2000-11-15
DK0612250T3 (da) 1996-11-25
JPH07501210A (ja) 1995-02-09
CA2115565C (en) 2007-08-07
DE69212495T2 (de) 1997-03-06
AU2487892A (en) 1993-03-16
CA2115565A1 (en) 1993-03-04

Similar Documents

Publication Publication Date Title
NO308413B1 (no) Antigen blanding, DNA-segment som koder for et antigen, rekombinant vektor og vertscelle som innbefatter DNA-segmentet samt anvendelser av et antigen
DE69229476T2 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
AU585512B2 (en) Antigenic proteins and vaccines containing them and protective antibodies directed to them for prevention of coccidiosis caused by eimeria tenella and eimeria necatrix
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DE3750139D1 (de) Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
DK482788A (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
DK0439056T3 (da) Coccidiose-vacciner
ATE124420T1 (de) Impfstoffe und testsätze für haemophilus influenzae.
Takagi et al. Purification of hemagglutinin from Haemophilus paragallinarum using monoclonal antibody
ATE315649T1 (de) Mycoplasma mycoides subsp. mycoides sc antigenisches lppq protein, seine herstellung und verwendung
WO1996034884A3 (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparation and use
FI894048A (fi) Menetelmä Pseudomonas aeruginosa-infektioita vastaan vaikuttavien valmisteiden sekä immunoglobuliini-G-pitoisten, Pseudomonas aeruginosa-bakteeria vastaan vaikuttavien valmisteiden tuottamiseksi
Kothari et al. Immunoscreening of a S. aureus gene bank with sera from endocarditis patients to isolate clones encoding antigens.